Extracellular Vesicles in Wound Healing Treatment: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Alessandro Sarcinella
,
Saveria Femminò
,
Maria Felice Brizzi

Non-healing wound- and tissue-injury are commonly experienced worldwide by the aging population. The persistence of disease commonly leads to tissue infection, resulting in severe clinical complications. Extracellular vesicles (EVs) have been considered promising and emergent therapeutic tools to improve the healing processes. Therefore, efforts have been directed to develop a cell-free therapeutic platform based on EV administration to orchestrate tissue repair. EVs derived from different cell types, including fibroblast, epithelial, and immune cells are recruited to the injured sites and in turn take part in scar formation.

  • EVs
  • wound healing
  • therapeutics

1. Introduction

Tissue repair is a complex, dynamic, and highly regulated process that involves the activation of specific signaling pathways promoting the remodeling of the tissue microenvironment composed of various cell types. The first event, defined as hemostasis, consists of the activation of the intrinsic and extrinsic coagulation pathways to prevent blood loss; then immune cells, in particular monocytes, are recruited to the injury site where they remove debris and bacteria. The recruitment of inflammatory cells and platelets promotes fibroblast migration, which contributes to extracellular matrix (ECM) release thereby resulting in scarring [1]. This process is considered a universal event occurring across all multicellular organisms, thereby it can be speculated that most of the conserved mechanisms can be investigated in experimental models and inferred to the clinic for human application. A significant understanding of the straightforward cellular and molecular mechanisms of regeneration has been gained by studying different preclinical models [2]. Recently, a large number of studies have highlighted the potential of extracellular vesicles (EVs) in enhancing tissue remodeling [3][4]. Briefly, EVs are a heterogenous group of bilayer particles, which are classified based on different physical characteristics, including their size. Therefore, the updated classification refers to EVs as small/medium and large EVs [5]. Once released, EVs can reach recipient cells both locally and at distant sites and deliver their contents to elicit functional responses and promote phenotypic changes. All these changes are mainly dependent on the physiological or pathological status features of their cell of origin. This implies that the interactions with and the transfer of EVs to recipient cells can drive various biological effects on the target cell, ranging from the activation of specific physiological activities to the development of pathological programs [6]. Currently, research dissecting the mechanisms by which EVs from different sources display certain peculiarities impacting the healing processes is ongoing. The structural similarity of EVs to liposomes makes them ideal for therapeutic delivery. Additionally, EVs are considered a more advantageous platform over liposomes since they can better reproduce the cell membrane [7]. In addition, recent studies showed promising applications of EVs due to their cargo specificity and natural ability to cross various biological barriers, preserving and protecting their content from degradation [4][8]. During EV-based therapeutic development, the major issue is represented by the selection of the best cellular source [9]. For example, EVs from inflammatory cells [10] mediate different biological actions with respect to EVs from stem cells [11]. EV-based compounds are administered mostly by subcutaneous injection to multiple sites surrounding the wound area, showing a fascinating boost in wound healing and tissue regeneration via a variety of biological processes, including revascularization, neo-angiogenesis, cell proliferation, and motility [3]. Recently a pilot case-control study in humans showed the efficacy of serum-derived EVs in the treatment of ulcers not-responsive to conventional medications [12]. However, to move towards clinical application using EVs derived from cellular sources, particular attention must be devoted to cell culture conditions, yield, and scalability [13]. Therefore, in the last decade, several research articles focused their attention to the manufacture of EVs also derived from different types of fruit or vegetables [14], paving the way toward a new era of wound healing treatment, exploiting the potential of plant-derived EVs. Moreover, EVs can be further engineered by manipulating parental cells to produce particles with the desired features or can be directly modified to act as delivery tools for specific therapeutic agents [15]. All these features drive EV-based therapy toward a more personalized clinical application.

2. Stem-Cell-Derived EVs

Recently, stem-cell-based therapy has gained attention due to its pluripotency and the potent ability to secrete a large number of regenerative factors [16]. Indeed, stem cells, including embryonic stem cells (ESC), induced pluripotent stem (iPS) cells, and adult stem cells, demonstrated unique properties such as a high proliferation rate and boosted self-renewal potentials compared to committed and specialized cells [17]. Indeed, stem cells have been proposed to promote wound healing in a paracrine way, regulating different cell subsets, and EVs represent one of the most relevant paracrine mediators and the main contributors to stem cell efficacy [18]. In particular, stem-cell-derived EVs have been proven to stimulate angiogenesis and cellular regeneration by suppressing apoptotic pathways and modulating immunity in damaged tissues both in vitro and in vivo [19]. Noteworthy, the clinical application of stem-cell-based therapy has faced problems with storage, allocation, and risks of tumorigenesis [20]. Therefore, EVs, which, in contrast to stem cells, cannot self-replicate, are much more feasible in terms of potential tumour formation and, more importantly, are stable enough for long-term storage, even at room temperature after lyophilization [21]. In addition, EVs can be administered by several routes; for example, nebulized or lyophilized lung-stem-cell-derived EVs can be administered by inhalation to treat lung diseases [21][22]. All these properties provide the rationale to exploit stem-cell-derived EVs as a valuable alternative approach to stem cells. In this regard, EVs from human umbilical cord mesenchymal stem cells (hucMSCs) promote angiogenesis and wound healing by activating the Wnt/β-catenin pathway by exosomal Wnt4a in a rat skin burn model [23], and reduce scar formation and myofibroblast accumulation in a skin-defect mouse model [24] by inhibiting the TGFβ2/SMAD2 pathway through exosomal microRNAs (miR-21, -23a, -125b, and -145). Furthermore, EVs isolated from human-induced-pluripotent-stem-cell-derived mesenchymal stem cells (hiPSC-MSCs) accelerate the re-epithelialization process through collagen promotion by triggering type I and III collagen and elastin secretion and mRNA expression by fibroblasts, resulting in scar-size decrease in a cutaneous-wound rat model [25]. A similar study demonstrated that EVs from human-induced-pluripotent-stem-cell-derived keratinocytes (hiPSCs-KCs) boost skin repair in a murine model of deep second-degree burn thanks to the enrichment of miR-762, which is involved in the promotion of keratinocyte and endothelial cell migration [26]. Moreover, in an aged mouse model of pressure-induced ulcer, EVs purified from human embryonic stem cells (ESC) were able to rejuvenate senescent endothelial cells and recover their proliferation and migratory capacity by Nrf2 activation via transference of miR-200a [27]. Similarly, Li X. et al. [28] demonstrated the therapeutic effect of EVs secreted by adipose-derived stem cells (ADSCs) overexpressing Nrf2 in the high glucose-induced senescence of endothelial progenitor cells using a diabetic rat model of diabetic foot ulcers. At this regard, ADSCs arouse great interest due to their great availability and easy isolation procedures that make their derivatives, like EVs, more appealing in preclinical and clinical settings [29][30]. Interestingly, Pomatto M. et al. [11] showed different therapeutic effect of EVs from ADSCs and bone marrow-derived stem cells (BMDSCs) in a mouse diabetic model of ulcers. Indeed, they demonstrated that BMSC-EVs mainly affected cell proliferation and viability of fibroblasts, keratinocytes, and endothelial cells, while ADSC-EVs showed a significant improved ability to promote endothelial cell migration and angiogenesis in vitro. However, in the in vivo experiments, only ADSCs-EVs were able to significantly reduce the wound size and induce an increased epithelial thickness, re-epithelization, and neo-vessel formation [11]. All these data indicate the mechanisms trough which stem cell-derived EVs can act at different levels during the wound healing processes. Therefore, since it appears that the cellular stem cell source and the EV cargoes could affect distinct repair processes the importance of selecting the best EV source to optimize the therapeutic efficacy is mandatory.

3. Macrophage-Derived EVs

Immune cells evolved as the primary defense against pathogenic wound invasion. Indeed, the immune response is initiated by injury-induced signals released by necrotic cells, damaged tissue, and bacterial components, which in turn activate resident immune cells to elicit downstream inflammatory pathways [31][32]. Specifically, in response to pro-inflammatory signals, neutrophils are recruited to the injured site to remove necrotic tissue and pathogens [33]. However, following the entrance of neutrophils, circulating monocytes move into the wound tissue where, in response to the local milieu, differentiate into macrophages. Thus, macrophages may be considered master effector cells in tissue repair [34]. Wound macrophages are classified into two main subsets: M1 (pro-inflammatory) and M2 (anti-inflammatory), possessing both pro-inflammatory and healing properties. Noteworthy, anti-inflammatory macrophages release a huge amount of growth factors to promote re-epithelialization, fibroplasia, and angiogenesis [35][36]. The effect of EVs derived from macrophages displaying different phenotypes on cutaneous healing has been recently analyzed [37]. Importantly, in a mouse model of skin-wound, studying bone-marrow-derived-macrophages, it was found that M2-macrophage-derived EVs (M2-EVs) induce macrophage reprogramming from the M1 to the M2 phenotype, resulting in sustained angiogenesis, re-epithelialization, and collagen deposition. Similarly, it has been recently demonstrated how macrophage-derived EVs recovered from adipose tissue efficiently modulate macrophage polarization, promoting the shift from M1 to M2, through the miR-222-3p/Bim axis. This translates into boosting diabetic wound healing when administered to diabetes-prone mice [38]. Indeed, it has been recently discovered that M1 polarization predominates in diabetic skin tissue, affecting the healing process; in particular, M1-derived EVs containing miR-503 lead to endothelial cell dysfunction, targeting IGF1R and thus inhibiting cell viability, tube formation, and cell migration [10]. Based on these notions, it can be speculated that the phenotype switch induced by EVs harboring a farfetched cell-reprogramming capability can represent a promising therapeutic approach for wound healing purposes by regulating the balance between the M1–M2 state. However, macrophage-derived EVs can exert their effect not only by reverting the phenotype but also by directly targeting cells within the wound site. Li M. et al. have found that EVs derived from RAW 264.7 cells significantly attenuated the secretion of pro-inflammatory cytokines and promoted the proliferation and migration of endothelial cells, improving de novo vessel formation in a skin-defect diabetic rat model [39]. Interestingly, in a recent work by Deng F. et al., M2-polarized Thp-1 cells secreted EVs enriched in miR-590-3p which promoted colonic epithelial cell proliferation via the LATS1/YAP/β-catenin signaling axis in a model of DSS-induced mucosal damage [40]. Notably, it has been recently reported that EVs isolated from the RAW 264.7 mouse macrophage cell line contain more pro-angiogenic factors, including VEGF, Wnt3a, and miR-130a, when compared to endothelial cells (HUVECs). Furthermore, it was observed that RAW-264.7-cell-derived EVs used for in vitro treatment significantly increase endothelial cell proliferation, migration, and tube formation, while use in vivo increases the formation of new and larger blood vessels [41]. These observations remark the pivotal role of the immune system, particularly macrophages, on the resolution of wound damage.

4. Platelet-Derived EVs (P-EVs)

Since P-EVs have an impact on several pathophysiological processes, such as angiogenesis, coagulation, and inflammation, they have been recently recognized as a promising therapeutic strategy for tissue regeneration [42]. Although there are many obstacles to using P-EVs in clinical practice, they are gaining attention due to their efficiency compared to platelets [43]. Indeed, in a model of immortalized human corneal endothelial cells, treatment with P-EVs did not exert cellular toxicity, maintaining cellular morphology and the preservation of corneal proteins. Corneal cells, which have a very limited regenerative ability, treated with P-EVs have shown increased proliferation and migration in a dose-dependent manner [43]. P-EV treatment has been also proposed for periodontal applications. Both gingival fibroblasts and keratinocytes were treated with P-EVs or with P-EVs combined with hyaluronic acid gels [44]; compared to the direct use of platelets, these treatments have shown regenerative effects and changes in the expression of genes related to extracellular matrix remodeling, including ACTA2, COL1A1 and DCN [44]. Guo et al. [45] reported that P-EVs increase proliferation and migration of endothelial cells (HMEC-1) and fibroblasts through activation of Erk and Akt signaling pathways. Consistently, in a clinical trial, EVs purified from platelets of healthy donors, determined the proliferation and migration of dermal fibroblasts compared to untreated cells through the phosphorylation of Erk and Akt [46]. In order to obtain a sustained drug release, P-EVs were combined with hydrogels and Resveratrol, an anti-inflammatory agent [47]. This combination, in a skin-wound model of diabetic mice, inhibits the inflammatory response and regulates macrophage phenotype transition and angiogenesis, leading to wound healing improvements [47]. Another in vivo wound healing study reported that chitosan/silk hydrogels loaded with P-EVs accelerate skin regeneration in diabetic rats [48]. In particular, accelerated wound healing, re-epithelialization, increased collagen synthesis, as well as dermal angiogenesis are described, thereby resulting in faster diabetic wound healing [48]. In conclusion, P-EVs alone or combined with different types of gels could be a promising bioengineering strategy in regenerative biotherapies.

5. Endothelial-Cell-Derived EVs (E-EVs)

Angiogenesis is a crucial step during the process of tissue regeneration. During wound healing, pre-existing vessels invade the wound clot and, within a few days, organize into a microvascular network. The cooperative regulation of endothelial cells, angiogenic cytokines, and the extracellular matrix environment stimulates angiogenesis to promote wound repair [49]. It has been extensively demonstrated that the stimulation of resident endothelial cells via paracrine mechanisms is more relevant than the direct differentiation into mature endothelial cells, and EVs play a major role in such paracrine action [50][51]. Indeed, it has been reported that EVs derived from endothelial progenitor cells (EPCs) were purified from healthy newborns and used to treat diabetic rats [52]. A wound-healing assay revealed that E-EVs affect the migration of endothelial cells and modulate the expression of various angiogenesis-related genes, including endothelial fibroblast growth factor1, interleukin-8, nitric oxide synthase, angiopoietin-1, E-selectin, vascular endothelial growth factor A, vascular endothelial growth factor receptor 2, and the chemokine ligand-16, thereby promoting angiogenesis [52]. Taken together, these findings draw attention to the role of E-EVs in promoting wound healing by modulating vascular endothelial cell behavior, thereby suggesting them as therapeutic tools for diabetic patients. In the context of diabetes, foot ulcers represent a serious clinical problem. Zeng et al. [53] demonstrated that miR-106b-5p could be a novel target to improve the healing of diabetic foot ulcers. Indeed, miR-106b-5p-containing small E-EVs were able to inhibit collagen synthesis by activating autophagy of human skin fibroblasts. This effect relies on Erk1/2-targeting in vitro and translates into a wound healing delay in vivo. Therefore, E-EVs enriched in miR-106b-5p would be a promising carrier to deliver siRNA or therapeutic drugs to promote wound healing in diabetic patients with foot ulcers. Consistently, miR-106b has been found as an inhibitor of skin-wound healing, thereby becoming a new therapeutic target [54].

This entry is adapted from the peer-reviewed paper 10.3390/ijms242115709

References

  1. Talbott, H.E.; Mascharak, S.; Griffin, M.; Wan, D.C.; Longaker, M.T. Wound healing, fibroblast heterogeneity, and fibrosis. Cell Stem Cell 2022, 29, 1161–1180.
  2. Al-Masawa, M.E.; Alshawsh, M.A.; Ng, C.Y.; Ng, A.M.H.; Foo, J.B.; Vijakumaran, U.; Subramaniam, R.; Ghani, N.A.A.; Witwer, K.W.; Law, J.X. Efficacy and safety of small extracellular vesicle interventions in wound healing and skin regeneration: A systematic review and meta-analysis of animal studies. Theranostics 2022, 12, 6455–6508.
  3. Narauskaitė, D.; Vydmantaitė, G.; Rusteikaitė, J.; Sampath, R.; Rudaitytė, A.; Stašytė, G.; Calvente, M.I.A.; Jekabsone, A. Extracellular Vesicles in Skin Wound Healing. Pharmaceuticals 2021, 14, 811.
  4. Wiklander, O.P.B.; Brennan, M.Á.; Lötvall, J.; Breakefield, X.O.; EL Andaloussi, S. Advances in therapeutic applications of extracellular vesicles. Sci. Transl. Med. 2019, 11, 492.
  5. Thery, J.D.A.C.; Witwer, K.W.; Aikawa, E.; Acaraz, M.J. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guide-lines. J. Extracell. Vesicles 2018, 7, 1535750.
  6. Van Niel, G.; D’Angelo, G.; Raposo, G. Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 2018, 19, 213–228.
  7. Liu, C.; Gao, H.; Lv, P.; Liu, J.; Liu, G. Extracellular vesicles as an efficient nanoplatform for the delivery of therapeutics. Hum. Vaccines Immunother. 2017, 13, 2678–2687.
  8. Alberro, A.; Iparraguirre, L.; Fernandes, A.; Otaegui, D. Extracellular Vesicles in Blood: Sources, Effects, and Applications. Int. J. Mol. Sci. 2021, 22, 8163.
  9. Wiklander, O.P.B.; Nordin, J.Z.; O’Loughlin, A.; Gustafsson, Y.; Corso, G.; Mäger, I.; Vader, P.; Lee, Y.; Sork, H.; Seow, Y.; et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J. Extracell. Vesicles 2015, 4, 26316.
  10. Wang, J.; Han, Y.; Huang, F.; Tang, L.; Mu, J.; Liang, Y. Diabetic macrophage small extracellular vesicles-associated miR-503/IGF1R axis regulates endothelial cell function and affects wound healing. Front. Immunol. 2023, 14, 1104890.
  11. Pomatto, M.; Gai, C.; Negro, F.; Cedrino, M.; Grange, C.; Ceccotti, E.; Togliatto, G.; Collino, F.; Tapparo, M.; Figliolini, F.; et al. Differential Therapeutic Effect of Extracellular Vesicles Derived by Bone Marrow and Adipose Mesenchymal Stem Cells on Wound Healing of Diabetic Ulcers and Correlation to Their Cargoes. Int. J. Mol. Sci. 2021, 22, 3851.
  12. Gibello, L.; D’antico, S.; Salafia, M.; Senetta, R.; Pomatto, M.A.C.; Orlando, G.; Sarcinella, A.; Lopatina, T.; Quaglino, P.; Lorenzi, M.; et al. First pilot case-control interventional study using autologous extracellular vesicles to treat chronic venous ulcers unresponsive to conventional treatments. Pharmacol. Res. 2023, 190, 106718.
  13. Reiner, A.T.; Witwer, K.W.; van Balkom, B.W.; de Beer, J.; Brodie, C.; Corteling, R.L.; Gabrielsson, S.; Gimona, M.; Ibrahim, A.G.; de Kleijn, D.; et al. Concise Review: Developing Best-Practice Models for the Therapeutic Use of Extracellular Vesicles. STEM CELLS Transl. Med. 2017, 6, 1730–1739.
  14. Dad, H.A.; Gu, T.-W.; Zhu, A.-Q.; Huang, L.-Q.; Peng, L.-H. Plant Exosome-like Nanovesicles: Emerging Therapeutics and Drug Delivery Nanoplatforms. Mol. Ther. 2020, 29, 13–31.
  15. Lu, S.; Lu, L.; Liu, Y.; Li, Z.; Fang, Y.; Chen, Z.; Zhou, J. Native and engineered extracellular vesicles for wound healing. Front. Bioeng. Biotechnol. 2022, 10, 1053217.
  16. Behr, B.; Ko, S.H.; Wong, V.W.; Gurtner, G.C.; Longaker, M.T. Stem Cells. Plast. Reconstr. Surg. 2010, 126, 1163–1171.
  17. Zhang, K.; Cheng, K. Stem cell-derived exosome versus stem cell therapy. Nat. Rev. Bioeng. 2023, 1, 608–609.
  18. An, Y.; Lin, S.; Tan, X.; Zhu, S.; Nie, F.; Zhen, Y.; Gu, L.; Zhang, C.; Wang, B.; Wei, W.; et al. Exosomes from adipose-derived stem cells and application to skin wound healing. Cell Prolif. 2021, 54, e12993.
  19. Derkus, B.; Emregul, K.C.; Emregul, E. A new approach in stem cell research-Exosomes: Their mechanism of action via cellular pathways. Cell Biol. Int. 2017, 41, 466–475.
  20. Trounson, A.; McDonald, C. Stem Cell Therapies in Clinical Trials: Progress and Challenges. Cell Stem Cell 2015, 17, 11–22.
  21. Popowski, K.D.; Moatti, A.; Scull, G.; Silkstone, D.; Lutz, H.; Abad, B.L.d.J.; George, A.; Belcher, E.; Zhu, D.; Mei, X.; et al. Inhalable dry powder mRNA vaccines based on extracellular vesicles. Matter 2022, 5, 2960–2974.
  22. Popowski, K.D.; Abad, B.L.d.J.; George, A.; Silkstone, D.; Belcher, E.; Chung, J.; Ghodsi, A.; Lutz, H.; Davenport, J.; Flanagan, M.; et al. Inhalable exosomes outperform liposomes as mRNA and protein drug carriers to the lung. Extracell. Vesicle 2022, 1, 100002.
  23. Zhang, B.; Wu, X.; Zhang, X.; Sun, Y.; Yan, Y.; Shi, H.; Zhu, Y.; Wu, L.; Pan, Z.; Zhu, W.; et al. Human Umbilical Cord Mesenchymal Stem Cell Exosomes Enhance Angiogenesis Through the Wnt4/β-Catenin Pathway. Stem Cells Transl. Med. 2015, 4, 513–522.
  24. Fang, S.; Xu, C.; Zhang, Y.; Xue, C.; Yang, C.; Bi, H.; Qian, X.; Wu, M.; Ji, K.; Zhao, Y.; et al. Umbilical Cord-Derived Mesenchymal Stem Cell-Derived Exosomal MicroRNAs Suppress Myofibroblast Differentiation by Inhibiting the Transforming Growth Factor-β/SMAD2 Pathway During Wound Healing. STEM CELLS Transl. Med. 2016, 5, 1425–1439.
  25. Zhang, J.; Guan, J.; Niu, X.; Shangchun, G.; Guo, S.; Li, Q.; Xie, Z.; Zhang, C.; Wang, Y. Exosomes released from human induced pluripotent stem cells-derived MSCs facilitate cutaneous wound healing by promoting collagen synthesis and angiogenesis. J. Transl. Med. 2015, 13, 49.
  26. Bo, Y.; Yang, L.; Liu, B.; Tian, G.; Li, C.; Zhang, L.; Yan, Y. Exosomes from human induced pluripotent stem cells-derived keratinocytes accelerate burn wound healing through miR-762 mediated promotion of keratinocytes and endothelial cells migration. J. Nanobiotechnology 2022, 20, 1–13.
  27. Chen, B.; Sun, Y.; Zhang, J.; Zhu, Q.; Yang, Y.; Niu, X.; Deng, Z.; Li, Q.; Wang, Y. Human embryonic stem cell-derived exosomes promote pressure ulcer healing in aged mice by rejuvenating senescent endothelial cells. Stem Cell Res. Ther. 2019, 10, 1–17.
  28. Li, X.; Xie, X.; Lian, W.; Shi, R.; Han, S.; Zhang, H.; Lu, L.; Li, M. Exosomes from adipose-derived stem cells overexpressing Nrf2 accelerate cutaneous wound healing by promoting vascularization in a diabetic foot ulcer rat model. Exp. Mol. Med. 2018, 50, 1–14.
  29. Jia, Q.; Zhao, H.; Wang, Y.; Cen, Y.; Zhang, Z. Mechanisms and applications of adipose-derived stem cell-extracellular vesicles in the inflammation of wound healing. Front. Immunol. 2023, 14, 1214757.
  30. Al-Ghadban, S.; Artiles, M.; Bunnell, B.A. Adipose Stem Cells in Regenerative Medicine: Looking Forward. Front. Bioeng. Biotechnol. 2021, 9, 837464.
  31. Chen, L.; DiPietro, L.A. Toll-Like Receptor Function in Acute Wounds. Adv. Wound Care 2017, 6, 344–355.
  32. Martin, P.; Leibovich, S.J. Inflammatory cells during wound repair: The good, the bad and the ugly. Trends Cell Biol. 2005, 15, 599–607.
  33. Kolaczkowska, E.; Kubes, P. Neutrophil recruitment and function in health and inflammation. Nat. Rev. Immunol. 2013, 13, 159–175.
  34. Das, A.; Sinha, M.; Datta, S.; Abas, M.; Chaffee, S.; Sen, C.K.; Roy, S. Monocyte and Macrophage Plasticity in Tissue Repair and Regeneration. Am. J. Pathol. 2015, 185, 2596–2606.
  35. Jetten, N.; Roumans, N.; Gijbels, M.J.; Romano, A.; Post, M.J.; de Winther, M.P.J.; Van Der Hulst, R.R.W.J.; Xanthoulea, S. Wound Administration of M2-Polarized Macrophages Does Not Improve Murine Cutaneous Healing Responses. PLoS ONE 2014, 9, e102994.
  36. Gurevich, D.B.; Severn, C.E.; Twomey, C.; Greenhough, A.; Cash, J.; Toye, A.M.; Mellor, H.; Martin, P. Live imaging of wound angiogenesis reveals macrophage orchestrated vessel sprouting and regression. EMBO J. 2018, 37, e97786.
  37. Kim, H.; Wang, S.Y.; Kwak, G.; Yang, Y.; Kwon, I.C.; Kim, S.H. Exosome-Guided Phenotypic Switch of M1 to M2 Macrophages for Cutaneous Wound Healing. Adv. Sci. 2019, 6, 1900513.
  38. Xia, W.; Liu, Y.; Jiang, X.; Li, M.; Zheng, S.; Zhang, Z.; Huang, X.; Luo, S.; Khoong, Y.; Hou, M.; et al. Lean adipose tissue macrophage derived exosome confers immunoregulation to improve wound healing in diabetes. J. Nanobiotechnology 2023, 21, 1–17.
  39. Li, M.; Wang, T.; Tian, H.; Wei, G.; Zhao, L.; Shi, Y. Macrophage-derived exosomes accelerate wound healing through their anti-inflammation effects in a diabetic rat model. Artif. Cells Nanomedicine Biotechnol. 2019, 47, 3793–3803.
  40. Deng, F.; Yan, J.; Lu, J.; Luo, M.; Xia, P.; Liu, S.; Wang, X.; Zhi, F.; Liu, D. M2 Macrophage-Derived Exosomal miR-590-3p Attenuates DSS-Induced Mucosal Damage and Promotes Epithelial Repair via the LATS1/YAP/ β-Catenin Signalling Axis. J. Crohn’s Colitis 2020, 15, 665–677.
  41. Gangadaran, P.; Rajendran, R.L.; Oh, J.M.; Hong, C.M.; Jeong, S.Y.; Lee, S.-W.; Lee, J.; Ahn, B.-C. Extracellular vesicles derived from macrophage promote angiogenesis In vitro and accelerate new vasculature formation In vivo. Exp. Cell Res. 2020, 394, 112146.
  42. Chaudhary, P.K.; Kim, S.; Kim, S. Shedding Light on the Cell Biology of Platelet-Derived Extracellular Vesicles and Their Biomedical Applications. Life 2023, 13, 1403.
  43. Widyaningrum, R.; Wu, Y.-W.; Delila, L.; Lee, D.-Y.; Wang, T.-J.; Burnouf, T. In vitro evaluation of platelet extracellular vesicles (PEVs) for corneal endothelial regeneration. Platelets 2022, 33, 1237–1250.
  44. Antich-Rosselló, M.; Munar-Bestard, M.; Forteza-Genestra, M.A.; Calvo, J.; Gayà, A.; Monjo, M.; Ramis, J.M. Evaluation of Platelet-Derived Extracellular Vesicles in Gingival Fibroblasts and Keratinocytes for Periodontal Applications. Int. J. Mol. Sci. 2022, 23, 7668.
  45. Guo, S.-C.; Tao, S.-C.; Yin, W.-J.; Qi, X.; Yuan, T.; Zhang, C.-Q. Exosomes derived from platelet-rich plasma promote the re-epithelization of chronic cutaneous wounds via activation of YAP in a diabetic rat model. Theranostics 2017, 7, 81–96.
  46. Johnson, J.; Law, S.Q.K.; Shojaee, M.; Hall, A.S.; Bhuiyan, S.; Lim, M.B.L.; Silva, A.; Kong, K.J.W.; Schoppet, M.; Blyth, C.; et al. First-in-human clinical trial of allogeneic, platelet-derived extracellular vesicles as a potential therapeutic for delayed wound healing. J. Extracell. Vesicles 2023, 12, e12332.
  47. Zhu, W.; Dong, Y.; Xu, P.; Pan, Q.; Jia, K.; Jin, P.; Zhou, M.; Xu, Y.; Guo, R.; Cheng, B. A composite hydrogel containing resveratrol-laden nanoparticles and platelet-derived extracellular vesicles promotes wound healing in diabetic mice. Acta Biomater. 2022, 154, 212–230.
  48. Xu, N.; Wang, L.; Guan, J.; Tang, C.; He, N.; Zhang, W.; Fu, S. Wound healing effects of a Curcuma zedoaria polysaccharide with platelet-rich plasma exosomes assembled on chitosan/silk hydrogel sponge in a diabetic rat model. Int. J. Biol. Macromol. 2018, 117, 102–107.
  49. Tonnesen, M.G.; Feng, X.; Clark, R.A. Angiogenesis in Wound Healing. J. Investig. Dermatol. Symp. Proc. 2000, 5, 40–46.
  50. Sahoo, S.; Klyachko, E.; Thorne, T.; Misener, S.; Schultz, K.M.; Millay, M.; Ito, A.; Liu, T.; Kamide, C.E.; Agrawal, H.; et al. Exosomes From Human CD34+ Stem Cells Mediate Their Proangiogenic Paracrine Activity. Circ. Res. 2011, 109, 724–728.
  51. Yang, G.; Waheed, S.; Wang, C.; Shekh, M.; Li, Z.; Wu, J. Exosomes and Their Bioengineering Strategies in the Cutaneous Wound Healing and Related Complications: Current Knowledge and Future Perspectives. Int. J. Biol. Sci. 2023, 19, 1430–1454.
  52. Li, X.; Jiang, C.; Zhao, J. Human endothelial progenitor cells-derived exosomes accelerate cutaneous wound healing in diabetic rats by promoting endothelial function. J. Diabetes Complicat. 2016, 30, 986–992.
  53. Zeng, T.; Wang, X.; Wang, W.; Feng, Q.; Lao, G.; Liang, Y.; Wang, C.; Zhou, J.; Chen, Y.; Liu, J.; et al. Endothelial cell-derived small extracellular vesicles suppress cutaneous wound healing through regulating fibroblasts autophagy. Clin. Sci. 2019, 133, CS20190008.
  54. Qi, L.; Lu, Y.; Wang, Z.; Zhang, G. microRNA-106b derived from endothelial cell–secreted extracellular vesicles prevents skin wound healing by inhibiting JMJD3 and RIPK3. J. Cell. Mol. Med. 2021, 25, 4551–4561.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Video Production Service
Feedback